12,611 Shares in TG Therapeutics, Inc. $TGTX Bought by Capstone Investment Advisors LLC

Capstone Investment Advisors LLC bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) during the second quarter, according to its most recent filing with the SEC. The firm bought 12,611 shares of the biopharmaceutical company’s stock, valued at approximately $693,000.

Other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of TG Therapeutics in the second quarter valued at about $1,211,429,000. Vanguard Group Inc. lifted its position in shares of TG Therapeutics by 2.1% during the 4th quarter. Vanguard Group Inc. now owns 15,841,002 shares of the biopharmaceutical company’s stock worth $472,220,000 after purchasing an additional 319,703 shares during the last quarter. State Street Corp lifted its position in shares of TG Therapeutics by 4.7% during the 4th quarter. State Street Corp now owns 8,479,999 shares of the biopharmaceutical company’s stock worth $252,789,000 after purchasing an additional 379,380 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in TG Therapeutics by 35.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,051,132 shares of the biopharmaceutical company’s stock valued at $61,144,000 after purchasing an additional 531,759 shares during the period. Finally, Pictet Asset Management Holding SA boosted its stake in TG Therapeutics by 19.6% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,747,373 shares of the biopharmaceutical company’s stock valued at $58,048,000 after purchasing an additional 286,325 shares during the period. Institutional investors own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. JPMorgan Chase & Co. lifted their price target on TG Therapeutics from $65.00 to $72.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Jefferies Financial Group restated a “buy” rating and issued a $83.00 price objective on shares of TG Therapeutics in a research note on Monday, June 22nd. Bank of America boosted their target price on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research report on Tuesday, July 7th. HC Wainwright reiterated a “buy” rating and set a $78.00 target price on shares of TG Therapeutics in a research note on Tuesday, August 4th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a report on Wednesday, July 29th. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $63.00.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $53.93 on Friday. The stock has a 50 day moving average of $53.37 and a two-hundred day moving average of $41.82. The company has a current ratio of 4.27, a quick ratio of 3.72 and a debt-to-equity ratio of 1.23. TG Therapeutics, Inc. has a 12 month low of $26.76 and a 12 month high of $59.30. The company has a market capitalization of $8.26 billion, a P/E ratio of 19.68, a P/E/G ratio of 2.39 and a beta of 1.62.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The firm had revenue of $240.34 million for the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business’s revenue for the quarter was up 70.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.17 earnings per share. As a group, equities analysts expect that TG Therapeutics, Inc. will post 0.92 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.